Frontiers in Clinical Drug Research: HIV

Frontiers in Clinical Drug Research: HIV

Volume: 4

Indexed in: Scopus, EBSCO.

Frontiers in Clinical Drug Research – HIV is a book series that brings updated reviews to readers interested in learning about advances in the development of pharmaceutical agents for the treatment ...
[view complete introduction]

US $
30

*(Excluding Mailing and Handling)



Syntheses of FDA Approved Integrase Inhibitor HIV Drugs and Improved Manufacturing using Flow Processing

Pp. 61-104 (44)

Omobolanle Janet Jesumoroti, Faith Akwi and Paul Watts

Abstract

A number of new antiviral drugs have made HIV/AIDS a manageable disease by the introduction of integrase strand transfer inhibitors. One of the major concerns is the accessibility of these drugs in lower income countries. Thus, adequate supplies and cost effective syntheses of these drugs via flow technology are of great importance. Presently, there are four integrase strand transfer inhibitors approved by FDA. This chapter will focus on the published synthesis of currently FDA approved integrase inhibitor drugs and other HIV drugs developed through flow technology. Thus hoping that such a review could be useful to scientists and academia desiring a greater understanding of HIV integrase drug development at reduced cost and could serve as a context for further research and possible collaboration with the industry.

Keywords:

Active pharmaceutical intermediate, Batch synthesis, Continuous flow synthesis, Food and drug administration, HIV/AIDS, HIV integrase, HIV protease, Integrase strand transfer inhibitor, Microreactors, Process development.

Affiliation:

Nelson Mandela University, University Way, Port Elizabeth, 6031, South Africa.